scholarly journals Intratumoral recombinant human interferon alpha-2a and vincristine combination therapy in canine transmissible venereal tumour

2018 ◽  
Vol 4 (4) ◽  
pp. 364-372 ◽  
Author(s):  
Halit Kanca ◽  
Gizem Tez ◽  
Kazim Bal ◽  
Dogukan Ozen ◽  
Eray Alcigir ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Interferon Alpha ◽  
Human Interferon ◽  
Canine Transmissible Venereal Tumour ◽  
Transmissible Venereal Tumour

Occurrence of clinical depression during combination therapy with pegylated interferon alpha or natural human interferon beta plus ribavirin

2011 ◽  
Vol 42 (3) ◽  
pp. 241-247 ◽  
Author(s):  
Hideyuki Nomura ◽  
Yuugou Miyagi ◽  
Hironori Tanimoto ◽  
Nobuyuki Yamashita ◽  
Seiji Oohashi ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Interferon Alpha ◽  
Interferon Beta ◽  
Pegylated Interferon ◽  
Clinical Depression ◽  
Human Interferon ◽  
Pegylated Interferon Alpha

scholarly journals Combination Regimens of Favipiravir Plus Interferon Alpha Inhibit Chikungunya Virus Replication in Clinically Relevant Human Cell Lines

2021 ◽  
Vol 9 (2) ◽  
pp. 307
Author(s):  
Evelyn J. Franco ◽  
Xun Tao ◽  
Kaley C. Hanrahan ◽  
Jieqiang Zhou ◽  
Jürgen B. Bulitta ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Antiviral Activity ◽  
Viral Replication ◽  
Cell Lines ◽  
Interferon Alpha ◽  
Chikungunya Virus ◽  
Plaque Assay ◽  
Human Infection ◽  
Viral Burden ◽  
Combination Regimens

Chikungunya virus (CHIKV) is an alphavirus associated with a broad tissue tropism for which no antivirals or vaccines are approved. This study evaluated the antiviral potential of favipiravir (FAV), interferon-alpha (IFN), and ribavirin (RBV) against CHIKV as mono- and combination-therapy in cell lines that are clinically relevant to human infection. Cells derived from human connective tissue (HT-1080), neurons (SK-N-MC), and skin (HFF-1) were infected with CHIKV and treated with different concentrations of FAV, IFN, or RBV. Viral supernatant was sampled daily and the burden was quantified by plaque assay on Vero cells. FAV and IFN were the most effective against CHIKV on various cell lines, suppressing the viral burden at clinically achievable concentrations; although the degree of antiviral activity was heavily influenced by cell type. RBV was not effective and demonstrated substantial toxicity, indicating that it is not a feasible candidate for CHIKV. The combination of FAV and IFN was then assessed on all cell lines. Combination therapy enhanced antiviral activity in HT-1080 and SK-N-MC cells, but not in HFF-1 cells. We developed a pharmacokinetic/pharmacodynamic model that described the viral burden and inhibitory antiviral effect. Simulations from this model predicted clinically relevant concentrations of FAV plus IFN completely suppressed CHIKV replication in HT-1080 cells, and considerably slowed down the rate of viral replication in SK-N-MC cells. The model predicted substantial inhibition of viral replication by clinical IFN regimens in HFF-1 cells. Our results highlight the antiviral potential of FAV and IFN combination regimens against CHIKV in clinically relevant cell types.

13 Native Human Interferon-Alpha Species Assessed for Immunoregulatory Properties

1983 ◽  
Vol 3 (2) ◽  
pp. 231-239 ◽  
Author(s):  
I. HERON ◽  
M. HOKLAND ◽  
K. BERG
Keyword(s):  
Interferon Alpha ◽  
Human Interferon

Influence of carbohydrates on the stability and structure of a hyperglycosylated human interferon alpha mutein

Biochimie ◽  
2010 ◽  
Vol 92 (8) ◽  
pp. 971-978 ◽  
Author(s):  
Natalia Ceaglio ◽  
Marina Etcheverrigaray ◽  
Ricardo Kratje ◽  
Marcos Oggero
Keyword(s):  
Interferon Alpha ◽  
Human Interferon ◽  
The Stability
Sign in / Sign up

Export Citation Format

Share Document